128 related articles for article (PubMed ID: 8837383)
1. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population.
Eis-Hübinger AM; Oldenburg J; Brackmann HH; Matz B; Schneweis KE
Zentralbl Bakteriol; 1996 Jul; 284(2-3):232-40. PubMed ID: 8837383
[TBL] [Abstract][Full Text] [Related]
2. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
[TBL] [Abstract][Full Text] [Related]
3. Parvovirus B19 infection in patients with hemophilia.
Ragni MV; Koch WC; Jordan JA
Transfusion; 1996 Mar; 36(3):238-41. PubMed ID: 8604509
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients.
Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN
Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402
[TBL] [Abstract][Full Text] [Related]
6. Detection of IgE anti-parvovirus B19 and increased CD23+ B cells in parvovirus B19 infection: relation to Th2 cytokines.
Bluth MH; Norowitz KB; Chice S; Shah VN; Nowakowski M; Josephson AS; Durkin HG; Smith-Norowitz TA
Clin Immunol; 2003 Aug; 108(2):152-8. PubMed ID: 12921761
[TBL] [Abstract][Full Text] [Related]
7. Persistence of parvovirus B19 DNA in synovium of patients with haemophilic arthritis.
Zakrzewska K; Azzi A; De Biasi E; Radossi P; De Santis R; Davoli PG; Tagariello G
J Med Virol; 2001 Oct; 65(2):402-7. PubMed ID: 11536251
[TBL] [Abstract][Full Text] [Related]
8. Parvovirus B19 quiescence during the course of human immunodeficiency virus infection in persons with hemophilia.
Goedert JJ; Erdman DD; Konkle BA; Török TJ; Lederman MM; Kleinert D; Mandalaki T; Kessler CM; Anderson LJ; Luban NL
Am J Hematol; 1997 Dec; 56(4):248-51. PubMed ID: 9395187
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus.
van Elsacker-Neile AM; Kroon FP; van der Ende ME; Salimans MM; Spaan WJ; Kroes AC
Clin Infect Dis; 1996 Dec; 23(6):1255-60. PubMed ID: 8953068
[TBL] [Abstract][Full Text] [Related]
11. Antibody response to B19 parvovirus VP1 and VP2 linear epitopes in patients with haemophilic arthritis.
Azzi A; Manaresi E; Zakrzewska K; DeSantis R; Musiani M; Zerbini M
J Med Virol; 2004 Apr; 72(4):679-82. PubMed ID: 14981773
[TBL] [Abstract][Full Text] [Related]
12. Parvovirus B19 infection in Hong Kong.
Lim WL; Wong KF; Lau CS
J Infect; 1997 Nov; 35(3):247-9. PubMed ID: 9459396
[TBL] [Abstract][Full Text] [Related]
13. Seroprevalence of parvovirus B19 in fibromyalgia syndrome.
Buyukkose M; Kozanoglu E; Basaran S; Bayramoglu O; Yarkin F
Clin Rheumatol; 2009 Mar; 28(3):305-9. PubMed ID: 19057847
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.
Rollag H; Patou G; Pattison JR; Degré M; Evensen SA; Fröland SS; Glomstein A
Scand J Infect Dis; 1991; 23(6):675-9. PubMed ID: 1815327
[TBL] [Abstract][Full Text] [Related]
15. Seroprevalence of human parvovirus B19 in children of a desert region.
Alsaeid K; Alsaeid M; Essa S; Dimitrov D; Pacsa A
Ann Trop Paediatr; 1996 Sep; 16(3):255-7. PubMed ID: 8893957
[TBL] [Abstract][Full Text] [Related]
16. [Prevalence of anti-human parvovirus B19 IgG antibody among blood donors in Jilin province].
Wei Q; Li Y; Wang JW; Wang H; Qu JG; Hung T
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):60-2. PubMed ID: 16816866
[TBL] [Abstract][Full Text] [Related]
17. [Investigation of parvovirus B19 seroprevalence in various age groups in Central Anatolia Region, Turkey].
Türk Dağı H; Ozdemir M; Baykan M; Baysal B
Mikrobiyol Bul; 2010 Jul; 44(3):467-72. PubMed ID: 21063997
[TBL] [Abstract][Full Text] [Related]
18. Seroepidemiology of parvovirus B19 in the Frankfurt am Main area, Germany: evaluation of risk factors.
Reinheimer C; Allwinn R; Doerr HW; Wittek M
Infection; 2010 Oct; 38(5):381-5. PubMed ID: 20556472
[TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of human parvovirus B19 in a suburban population in São Paulo, Brazil.
Huatuco EM; Durigon EL; Lebrun FL; Passos SD; Gazeta RE; Azevedo Neto RS; Massad E
Rev Saude Publica; 2008 Jun; 42(3):443-9. PubMed ID: 18425294
[TBL] [Abstract][Full Text] [Related]
20. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples.
Beersma MF; Claas EC; Sopaheluakan T; Kroes AC
J Clin Virol; 2005 Sep; 34(1):71-5. PubMed ID: 15985386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
